lncRNA/MicroRNA interactions in the vasculature

Clinical Pharmacology and Therapeutics

Volumn 99, Issue 5, 2016, Pages 494-501

  Ballantyne, M D ^a,b   McDonald, R A ^a   Baker, A H ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; LINCRNA MD1; LINCRNA P21; LONG UNTRANSLATED RNA; LONG UNTRANSLATED RNA 362; MICRORNA; MICRORNA 130B; MICRORNA 133B; MICRORNA 135; MICRORNA 206; MICRORNA 221; MICRORNA 222; MICRORNA 382 5P; MICRORNA 4459; MICRORNA 4488; MIRNA LET 7; NUCLEAR FACTOR I; NUCLEAR FACTOR IA; RNA H19; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG; UNTRANSLATED RNA; BIOLOGICAL MARKER;

ARTICLE; BIOSYNTHESIS; ENDOTHELIUM CELL; GENE CONTROL; GENE FUNCTION; GENE INTERACTION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; INTERACTIONS WITH RNA; NONHUMAN; OVERLAPPING GENE; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RNA STABILITY; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE CELL; VASCULARIZATION; ANGIOGENESIS; ANIMAL; APOPTOSIS; CELL MOTION; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; VASCULAR DISEASES;

ANIMALS; APOPTOSIS; BIOMARKERS; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION; HUMANS; MICRORNAS; NEOVASCULARIZATION, PHYSIOLOGIC; RNA, LONG NONCODING; VASCULAR DISEASES;

EID: 84962792154     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.355     Document Type: Article

References (67)

1. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385(9963), 117-171 (2015).
2. Wang J., et al. CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res. 38(16), 5366-5383 (2010).
3. West N.E., et al. Nitric oxide synthase (nNOS) gene transfer modifies venous bypass graft remodeling: effects on vascular smooth muscle cell differentiation and superoxide production. Circulation 104(13), 1526-1532 (2001).
4. Buttery L.D., et al. Explanted vein grafts with an intact endothelium demonstrate reduced focal expression of endothelial nitric oxide synthase specific to atherosclerotic sites. J. Pathol. 179(2), 197-203 (1996).
5. Libby P., Ridker P.M., & Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature 473(7347), 317-325 (2011).
6. Chamberlain J., et al. Interleukin-1beta and signaling of interleukin-1 in vascular wall and circulating cells modulates the extent of neointima formation in mice. Am. J. Pathol. 168(4), 1396-1403 (2006).
7. Rectenwald J.E., Moldawer L.L., Huber T.S., Seeger J.M., & Ozaki C.K. Direct evidence for cytokine involvement in neointimal hyperplasia. Circulation 102(14), 1697-1702 (2000).
8. Isoda K., et al. Deficiency of interleukin-1 receptor antagonist promotes neointimal formation after injury. Circulation 108(5), 516-518 (2003).
9. Elhage R., et al. Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice. Circulation 97(3), 242-244 (1998).
10. Liu R., Leslie K.L., & Martin K.A. Epigenetic regulation of smooth muscle cell plasticity. Biochim. Biophys. Acta 1849(4), 448-453 (2015).
11. McDonald R.A., Hata A., MacLean M.R., Morrell N.W., & Baker A.H. MicroRNA and vascular remodelling in acute vascular injury and pulmonary vascular remodelling. Cardiovasc. Res. 93(4), 594-604 (2012).
12. Ferns G.A., et al. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 253(5024), 1129-1132 (1991).
13. Fingerle J., Au Y.P., Clowes A.W., & Reidy M.A. Intimal lesion formation in rat carotid arteries after endothelial denudation in absence of medial injury. Arteriosclerosis 10(6), 1082-1087 (1990).
14. Lindner V., & Reidy M.A. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc. Natl. Acad. Sci. U. S. A. 88(9), 3739-3743 (1991).
15. Rutherford C., et al. Substantial inhibition of neo-intimal response to balloon injury in the rat carotid artery using a combination of antibodies to platelet-derived growth factor-BB and basic fibroblast growth factor. Atherosclerosis 130(1-2), 45-51 (1997).
16. Reidy M.A., Irvin C., & Lindner V. Migration of arterial wall cells. Expression of plasminogen activators and inhibitors in injured rat arteries. Circ. Res. 78(3), 405-414 (1996).
17. George S.J. Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis. Expert Opin. Investig. Drugs. 9(5), 993-1007 (2000).
18. Southgate K.M., et al. Upregulation of basement membranedegrading metalloproteinase secretion after balloon injury of pig carotid arteries. Circ. Res. 79(6), 1177-1187 (1996).
19. Zempo N., et al. Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid artery. J. Vasc. Surg. 20(2), 209-217 (1994).
20. International Human Genome Sequencing Collaborators. Finishing the euchromatic sequence of the human genome. Nature 431(7011), 931-945 (2004).
21. Wilusz J.E., Sunwoo H., & Spector D.L. Long noncoding RNAs: functional surprises from the RNA world. Genes Dev. 23(13), 1494-1504 (2009).
22. Derrien T., et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 22(9), 1775-1789 (2012).
23. Trefzer U., et al. SM5-1: a new monoclonal antibody which is highly sensitive and specific for melanocytic lesions. Arch. Dermatol. Res. 292(12), 583-589 (2000).
24. Takemoto N., et al. Small-molecule-induced clustering of heparan sulfate promotes cell adhesion. J. Am. Chem. Soc. 135(30), 11032-11039 (2013).
25. Scheuermann J.C., & Boyer L.A. Getting to the heart of the matter: long non-coding RNAs in cardiac development and disease. EMBO J. 32(13), 1805-1816 (2013).
26. Wang K.C., & Chang H.Y. Molecular mechanisms of long noncoding RNAs. Mol. Cell 43(6), 904-914 (2011).
27. Ebert M.S., & Sharp P.A. Emerging roles for natural microRNA sponges. Curr. Biol. 20(19), R858-861 (2010).
28. Xia T., et al. Long noncoding RNA associated-competing endogenous RNAs in gastric cancer. Sci. Rep. 4, 6088 (2014).
29. Carthew R.W., & Sontheimer E.J. Origins and mechanisms of miRNAs and siRNAs. Cell 136(4), 642-655 (2009).
30. Rodriguez A., Griffiths-Jones S., Ashurst J.L., & Bradley A. Identification of mammalian microRNA host genes and transcription units. Genome Res. 14(10A), 1902-1910 (2004).
31. Munshi N., Fernandis A.Z., Cherla R.P., Park I.W., & Ganju R.K. Lipopolysaccharide-induced apoptosis of endothelial cells and its inhibition by vascular endothelial growth factor. J. Immunol. 168(11), 5860-5866 (2002).
32. Huang S., et al. A new microRNA signal pathway regulated by long noncoding RNA TGFB2-OT1 in autophagy and inflammation of vascular endothelial cells. Autophagy 11, 2172-2183 (2015).
33. Sun Y., et al. Smooth muscle cell-specific runx2 deficiency inhibits vascular calcification. Circ. Res. 111(5), 543-552 (2012).
34. Xia Z.Y., et al. Runx2/miR-3960/miR-2861 positive feedback loop is responsible for osteogenic transdifferentiation of vascular smooth muscle cells. Biomed. Res. Int. 2015, 624037 (2015).
35. Weiss D., Sorescu D., & Taylor, W, R. Angiotensin II and atherosclerosis. Am. J. Cardiol. 87(8A), 25C-32C (2001).
36. Leung A., et al. Novel long noncoding RNAs are regulated by angiotensin II in vascular smooth muscle cells. Circ. Res. 113(3), 266-278 (2013).
37. Liu X., et al. A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ. Res. 104(4), 476-487 (2009).
38. Davis B.N., Hilyard A.C., Nguyen P.H., Lagna G., & Hata A. Induction of microRNA-221 by platelet-derived growth factor signaling is critical for modulation of vascular smooth muscle phenotype. J. Biol. Chem. 284(6), 3728-3738 (2009).
39. Bazan H.A., et al. Acute Loss of miR-221 and miR-222 in the atherosclerotic plaque shoulder accompanies plaque rupture. Stroke 46(11), 3285-3287 (2015).
40. Weber C., & Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat, Med. 17(11), 1410-1422 (2011).
41. Zhu N., et al. Endothelial enriched microRNAs regulate angiotensin IIinduced endothelial inflammation and migration. Atherosclerosis 215(2), 286-293 (2011).
42. Liu N., et al. microRNA-206 promotes skeletal muscle regeneration and delays progression of Duchenne muscular dystrophy in mice. J. Clin. Invest. 122(6), 2054-2065 (2012).
43. Jalali S., et al. Mir-206 regulates pulmonary artery smooth muscle cell proliferation and differentiation. PLoS One 7(10), e46808 (2012).
44. Thum T., & Batkai S. MicroRNAs in right ventricular (dys)function (2013 Grover Conference series). Pulm. Circ. 4(2), 185-190 (2014).
45. Panizo S., et al. MicroRNAs 29b 133b, and 211 regulate vascular smooth muscle calcification mediated by high phosphorus. J. Am. Soc. Nephrol. 2015); e-pub ahead of print.
46. Cipollone F., et al. A unique microRNA signature associated with plaque instability in humans. Stroke 42(9), 2556-2563 (2011).
47. Brown K.W., et al. Imprinting mutation in the Beckwith-Wiedemann syndrome leads to biallelic IGF2 expression through an H19-independent pathway. Hum. Mol. Genet. 5(12), 2027-2032 (1996).
48. Kallen A.N. L, et al. The imprinted H19 lncRNA antagonizes let-7 microRNAs. Mol. Cell 52(1), 101-112 (2013).
49. Gabory A., Jammes H., & Dandolo L. The H19 locus: role of an imprinted non-coding RNA in growth and development. Bioessays 32(6), 473-480 (2010).
50. Kim D.K., Zhang L., Dzau V.J., & Pratt R.E. H19, a developmentally regulated gene, is reexpressed in rat vascular smooth muscle cells after injury. J. Clin. Invest. 93(1), 355-360 (1994).
51. Kinet V., Halkein J., Dirkx E., & Windt L.J. Cardiovascular extracellular microRNAs: emerging diagnostic markers and mechanisms of cell-Tocell RNA communication. Front. Genet. 4, 214 (2013).
52. Keniry A., et al. The H19 lincRNA is a developmental reservoir of miR-675 that suppresses growth and Igf1r. Nat. Cell. Biol. 14(7), 659-665 (2012).
53. Paralkar V.R., et al. Lineage and species-specific long noncoding RNAs during erythro-megakaryocytic development. Blood 123(12), 1927-1937 (2014).
54. Wu G., et al. LincRNA-p21 regulates neointima formation, vascular smooth muscle cell proliferation, apoptosis, and atherosclerosis by enhancing p53 activity. Circulation 130(17), 1452-1465 (2014).
55. Yoon J.H., et al. LincRNA-p21 suppresses target mRNA translation. Mol. Cell 47(4), 648-655 (2012).
56. Bertero T., et al. Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension. J. Clin. Invest. 124(8), 3514-3528 (2014).
57. Hu Y.W., et al. RP5-833A20.1/miR-382-5p/NFIA-dependent signal transduction pathway contributes to the regulation of cholesterol homeostasis and inflammatory reaction. Arterioscler. Thromb. Vasc. Biol. 35(1), 87-101 (2015).
58. Clark M.B., et al. Quantitative gene profiling of long noncoding RNAs with targeted RNA sequencing. Nat. Methods 12(4), 339-342 (2015).
59. Jiang X., & Ning Q. The emerging roles of long noncoding RNAs in common cardiovascular diseases. Hypertens. Res. 38(6), 375-379 (2015).
60. Sanchez Y., & Huarte M. Long non-coding RNAs: challenges for diagnosis and therapies. Nucleic Acids Ther. 23(1), 15-20 (2013).
61. Yang Y., et al. Plasma long non-coding RNA, CoroMarker, a novel biomarker for diagnosis of coronary artery disease. Clin. Sci. (Lond). 129(8), 675-685 (2015).
62. Janssen H.L., Kauppinen S., & Hodges M.R. HCV infection and miravirsen. N. Engl. J. Med. 369(9), 878 (2013).
63. Zimmermann T.S., et al. RNAi-mediated gene silencing in non-human primates. Nature 441(7089), 111-114 (2006).
64. Tabernero J., et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 3(4), 406-417 (2013).
65. Pedram Fatemi R., et al. Screening for small-molecule modulators of long noncoding RNA-protein interactions using AlphaScreen. J. Biomol. Screen. 20(9), 1132-1141 (2015).
66. Stelzer A.C., et al. Discovery of selective bioactive small molecules by targeting an RNA dynamic ensemble. Nat. Chem. Biol. 7(8), 553-559 (2011).
67. Winter J., Jung S., Keller S., Gregory R.I., & Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat. Cell. Biol. 11(3), 228-234 (2009).